Wednesday
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND RIVAROXABAN
Location: Grand Ballroom West, 3rd Floor
Moderators:Caron B. Rockman, MD / Michael R. Jaff, DO  
SESSION 31 SCHEDULE
6:40 AM - 6:45 AM Postop Myocardial Infarctions (MIs) In Vascular Patients: What Are The New Options For Diagnosis, Prevention And Treatment
  Presenter(s):Peter Henke, MD  
Location: Grand Ballroom West, 3rd Floor
6:46 AM - 6:51 AM What Is The Best Current Method For Evaluating The Heart In Patients Undergoing Open And Endo Vascular Surgery: When Is A Stress Test An Important Tool
  Presenter(s):David H. Stone, MD  
Location: Grand Ballroom West, 3rd Floor
6:52 AM - 6:57 AM New Findings From The VOYAGER PAD And COMPASS RCTs With Low Dose Rivaroxaban (Xarelto [Janssen/J&J]) And Aspirin: How Do These Drugs Lower Major Adverse Limb And Cardiac Event Rates After Lower Extremity Revascularization (Endo And Open)
  Presenter(s):Marianne Brodmann, MD / Sebastian E. Debus, MD, PhD  
Location: Grand Ballroom West, 3rd Floor
6:58 AM - 7:03 AM How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials
  Presenter(s):Anthony J. Comerota, MD, FACS, FACC  
Location: Grand Ballroom West, 3rd Floor
7:04 AM - 7:09 AM DEBATE: LDL Cholesterol (LDL-C) Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful: What Does The Latest Evidence Show
  Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC, PhD, FACS  
Location: Grand Ballroom West, 3rd Floor
7:10 AM - 7:15 AM DEBATE: Not So: Update On LDL-C Lowering With Statins And Other Drugs: They Are Proven To Stabilize And Shrink Plaques And Decrease Morbid Vascular Events: Stopping Statins Increases Patientsí Risk Of MI And Death
  Presenter(s):Ron Waksman, MD  
Location: Grand Ballroom West, 3rd Floor
7:16 AM - 7:21 AM The Risk Of Arteriosclerosis And Its Complications Are Increased By LDL Cholesterol (LDL-C) Levels, Elevated Lp(a) And Inflammation: What Are The Best Medical Strategies To Decrease These Parameters: Statins, Adjunctive LDL-C Lowering Drugs Inclisiran, Bempedoic Acid, Ezetimibe, PCSK-9 Inhibitors, Lepodisiran, Colchicine, Olezarsen, Etc.) And Anti-Inflammatories: How They Should Be Administered
  Presenter(s):Richard Bulbulia, MA, MD, FRCS  
Location: Grand Ballroom West, 3rd Floor
7:22 AM - 7:27 AM Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured
  Presenter(s):J. David Spence, MD  
Location: Grand Ballroom West, 3rd Floor
7:28 AM - 7:33 AM An Interesting New Anti-Atherosclerosis Vaccine (AtheroVax): A Drug To Produce Lifelong LDL-C Lowering With A Single Gene Modifying Treatment: The Heart-1 Gene-Editing Trial: How Does AtheroVax Work
  Presenter(s):Nicholas Kipshidze, MD, PhD, DSc  
Location: Grand Ballroom West, 3rd Floor
7:34 AM - 7:42 AM Panel Discussion
END OF SESSION 31
previous next